Literature DB >> 8223868

T cell-mediated cognate signaling of nitric oxide production by macrophages. Requirements for macrophage activation by plasma membranes isolated from T cells.

X Tao1, R D Stout.   

Abstract

Macrophage generation of reactive nitrogen intermediates (RNI) represents a major effector mechanism in anti-microbial immunity and non-septic inflammatory reactions. The induction of macrophage RNI production has been demonstrated to require at least two signals which in microbial infections can be provided by interferon (IFN)-gamma and lipopolysaccharide (LPS). The current study demonstrates that, in the absence of LPS, T lymphocytes can provide cognate signal(s) which synergize with IFN-gamma in stimulating macrophage RNI production, as evidenced by the ability of plasma membranes from T cell clones to activate IFN-gamma-primed macrophages. Although viable resting T cells can activate IFN-gamma-primed macrophages by an interaction that is antigen specific, plasma membranes from resting T cells do not active macrophages. Plasma membranes from T cells activated by immobilized anti-CD3 were able to effectively induce RNI production in IFN-gamma-primed macrophages. However, in contrast to the antigen-specific interaction of macrophages with viable resting T cells, the activation of IFN-gamma-primed macrophages by membranes from activated T cells does not display antigen specificity. Plasma membranes from activated T helper TH2 and from activated TH1 cells were equally effective in activating IFN-gamma-primed macrophages, suggesting that the dominance of TH1 over TH2 cells in cell-mediated responses involving macrophage effectors is not a reflection of differences in their ability to interact with macrophages but rather is a reflection of their different pattern of cytokine production. These results suggest that the T cell-macrophage interaction involves reciprocal activation of both cells--an antigen-specific activation of the T cells which results in the acquisition of T cell membrane components involved in antigen-nonspecific stimulation of the macrophages.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8223868     DOI: 10.1002/eji.1830231128

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  7 in total

Review 1.  The CD40 ligand. At the center of the immune universe?

Authors:  I S Grewal; R A Flavell
Journal:  Immunol Res       Date:  1997-02       Impact factor: 2.829

2.  Nitric oxide production in SJL mice bearing the RcsX lymphoma: a model for in vivo toxicological evaluation of NO.

Authors:  A Gal; S Tamir; S R Tannenbaum; G N Wogan
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-15       Impact factor: 11.205

3.  Nitric oxide-enhanced resistance to oral candidiasis.

Authors:  S Elahi; G Pang; R B Ashman; R Clancy
Journal:  Immunology       Date:  2001-12       Impact factor: 7.397

4.  Comparative studies on the roles of mediator molecules in expression of the suppressor activity of Mycobacterium avium complex-induced immunosuppressive macrophages against T cell and B cell mitogenic responses.

Authors:  S Cai; T Shimizu; H Tomioka
Journal:  Clin Exp Immunol       Date:  2006-03       Impact factor: 4.330

5.  By homing to the kidney, activated macrophages potently exacerbate renal injury.

Authors:  Ying Wang; Yiping Wang; Qi Cao; Qi Cai; Guoping Zheng; Vincent W S Lee; Dong Zheng; Xiaomei Li; Thian Kui Tan; David C H Harris
Journal:  Am J Pathol       Date:  2008-05-08       Impact factor: 4.307

6.  Contact-dependent stimulation of monocytic cells and neutrophils by stimulated human T-cell clones.

Authors:  J M Li; P Isler; J M Dayer; D Burger
Journal:  Immunology       Date:  1995-04       Impact factor: 7.397

7.  Triggering of human monocyte activation through CD69, a member of the natural killer cell gene complex family of signal transducing receptors.

Authors:  R De Maria; M G Cifone; R Trotta; M R Rippo; C Festuccia; A Santoni; R Testi
Journal:  J Exp Med       Date:  1994-11-01       Impact factor: 14.307

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.